losartan has been researched along with Fibromuscular Dysplasia in 3 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Fibromuscular Dysplasia: An idiopathic, segmental, nonatheromatous disease of the musculature of arterial walls, leading to STENOSIS of small and medium-sized arteries. There is true proliferation of SMOOTH MUSCLE CELLS and fibrous tissue. Fibromuscular dysplasia lesions are smooth stenosis and occur most often in the renal and carotid arteries. They may also occur in other peripheral arteries of the extremity.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Jafari, R | 1 |
| Rostami, Z | 1 |
| Nikpoor, M | 1 |
| Javanbakht, M | 1 |
| Ghahroudi, MS | 1 |
| Hosseini, MS | 1 |
| Einollahi, B | 1 |
| Tanemoto, M | 1 |
| Takase, K | 1 |
| Yamada, T | 1 |
| Satoh, A | 1 |
| Abe, T | 1 |
| Ito, S | 1 |
| Scholze, J | 1 |
1 review available for losartan and Fibromuscular Dysplasia
| Article | Year |
|---|---|
[Angiotensin II receptor antagonists. Clinical relevance].
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Drug Therapy, Combina | 1996 |
2 other studies available for losartan and Fibromuscular Dysplasia
| Article | Year |
|---|---|
Detection of significant left renal artery stenosis caused by fibromuscular dysplasia with selective angiography.
Topics: Amlodipine; Angioplasty, Balloon; Antihypertensive Agents; Computed Tomography Angiography; Drug Com | 2020 |
Dilation of renal artery stenosis after administration of losartan.
Topics: Adult; Angioplasty, Balloon; Antihypertensive Agents; Female; Fibromuscular Dysplasia; Humans; Hyper | 2007 |